The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis
Arthritis Res Ther. 2015 May 20;17(1):135. [Epub ahead of print]
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
Arthritis Res Ther. 2015 May 20;17(1):135. [Epub ahead of print]
Arthritis Res Ther. 2015 Apr 6;17(1):95.
Ann Rheum Dis. 2015 Apr 22. pii: annrheumdis-2014-205847. doi: 10.1136/annrheumdis-2014-205847. [Epub ahead of print]
Nature. 2015 Feb 16. doi: 10.1038/nature14154. [Epub ahead of print]
Arthritis Rheumatol. Vol. 67, No. 6, June 2015, pp 1424–1437
Arthritis Rheumatol. 2015;67(2):334–343.
Arthritis Rheumatol. 2015;67(3):616-25.
Mod J Clin Pharmacol. 2014 Dec;54(12):1354-61. doi: 10.1002/jcph.354.
PLoS One. 2014 Dec 5;9(12):e114195. doi: 10.1371/journal.pone.0114195. eCollection 2014.
Ann Rheum Dis. 2015;74(2):333–340